Introduction: Primary sclerosing cholangitis (PSC) is a chronic liver disease that can lead to complications, including hepatocellular carcinoma (HCC). However, the actual risk of developing HCC in PSC patients has been unclear, leading to questions about the necessity of current HCC surveillance guidelines.
Introduction:
Primary sclerosing cholangitis (PSC) is a chronic liver disease that can lead to complications, including hepatocellular carcinoma (HCC). However, the actual risk of developing HCC in PSC patients has been unclear, leading to questions about the necessity of current HCC surveillance guidelines.
Problem Statement:
A study involving 3071 PSC patients across 12 university hospitals was conducted to better understand the risk of HCC. Patients were followed for an average total of 38,387 person-years, from PSC diagnosis until death, liver transplantation, or other significant events. The study aimed to identify factors associated with HCC development, such as age and cirrhosis status, to refine surveillance strategies.
Conclusion:
The study found that HCC is relatively rare in PSC patients, especially in those without cirrhosis and under the age of 50. Cirrhosis was a significant risk factor for HCC, with most cases occurring in cirrhotic patients. Age also increased the risk, but for non-cirrhotic patients, the risk remained low across all age groups. These findings suggest that HCC surveillance in PSC patients can be tailored based on individual risk factors like age and cirrhosis status, potentially reducing unnecessary monitoring in low-risk groups.
Introduction: Metabolic dysfunction–associated steatotic liver disease (MASLD) is now the fastest-growing cause of hepatocellular carcinoma (HCC). Because a substantial proportion of MASLD-related HCC develops before cirrhosis, better tools are needed to identify high-risk patients who...
Introduction: The HIMALAYA trial established durvalumab plus tremelimumab (STRIDE) as a first-line treatment for unresectable hepatocellular carcinoma (HCC). However, many real-world patients do not meet the strict eligibility criteria of clinical trials. This multicenter study...
Introduction: Prognosis in unresectable hepatocellular carcinoma (HCC) depends not only on tumor burden but also on liver function and nutritional status. This study evaluated the prognostic value of ALBI grade, EZ-ALBI grade, and sarcopenia in...
Introduction: Hepatocellular carcinoma (HCC) surveillance enables earlier diagnosis and improves survival. This largest UK multicenter study evaluated how patients are diagnosed in routine clinical practice and identified major gaps in the surveillance pathway. Why was...
Introduction: Selective internal radiation therapy (SIRT) using yttrium-90 (Y90) glass microspheres is an established locoregional treatment for hepatocellular carcinoma (HCC), but guideline recommendations remain inconsistent. This large prospective multicenter study evaluated the real-world effectiveness, safety,...
Introduction: Atezolizumab–bevacizumab (A/B) and durvalumab–tremelimumab (STRIDE) are preferred first-line treatments for advanced hepatocellular carcinoma (HCC). Because bevacizumab inhibits VEGF, concerns remain regarding bleeding and thromboembolic complications in patients with underlying cirrhosis and portal hypertension. Why...
We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.